

# Anisur Rahman

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8304417/publications.pdf>

Version: 2024-02-01

191  
papers

12,353  
citations

53794

45  
h-index

26613

107  
g-index

196  
all docs

196  
docs citations

196  
times ranked

11522  
citing authors

#	ARTICLE	IF	CITATIONS
1	Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus. <i>Arthritis and Rheumatism</i> , 2012, 64, 2677-2686.	6.7	3,838
2	Systemic Lupus Erythematosus. <i>New England Journal of Medicine</i> , 2008, 358, 929-939.	27.0	1,548
3	Factors associated with damage accrual in patients with systemic lupus erythematosus: results from the Systemic Lupus International Collaborating Clinics (SLICC) Inception Cohort. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 1706-1713.	0.9	391
4	The frequency and outcome of lupus nephritis: results from an international inception cohort study. <i>Rheumatology</i> , 2016, 55, 252-262.	1.9	370
5	A framework for remission in SLE: consensus findings from a large international task force on definitions of remission in SLE (DORIS). <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 554-561.	0.9	268
6	Cancer risk in systemic lupus: An updated international multi-centre cohort study. <i>Journal of Autoimmunity</i> , 2013, 42, 130-135.	6.5	249
7	14th International Congress on Antiphospholipid Antibodies Task Force. Report on antiphospholipid syndrome laboratory diagnostics and trends. <i>Autoimmunity Reviews</i> , 2014, 13, 917-930.	5.8	224
8	Damage and mortality in a group of British patients with systemic lupus erythematosus followed up for over 10 years. <i>Rheumatology</i> , 2009, 48, 673-675.	1.9	204
9	Systemic lupus erythematosus. <i>Orphanet Journal of Rare Diseases</i> , 2006, 1, 6.	2.7	173
10	The use of Systemic Lupus Erythematosus Disease Activity Index-2000 to define active disease and minimal clinically meaningful change based on data from a large cohort of systemic lupus erythematosus patients. <i>Rheumatology</i> , 2011, 50, 982-988.	1.9	155
11	Seizure disorders in systemic lupus erythematosus results from an international, prospective, inception cohort study. <i>Annals of the Rheumatic Diseases</i> , 2012, 71, 1502-1509.	0.9	143
12	Binding of antiphospholipid antibodies to discontinuous epitopes on domain I of human Î²2-glycoprotein I: Mutation studies including residues R39 to R43. <i>Arthritis and Rheumatism</i> , 2007, 56, 280-290.	6.7	134
13	Lymphoma risk in systemic lupus: effects of disease activity versus treatment. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 138-142.	0.9	115
14	Effective Delivery Styles and Content for Self-management Interventions for Chronic Musculoskeletal Pain. <i>Clinical Journal of Pain</i> , 2012, 28, 344-354.	1.9	113
15	Numerical scoring for the BILAG-2004 index. <i>Rheumatology</i> , 2010, 49, 1665-1669.	1.9	111
16	Relationship between anti-dsDNA, anti-nucleosome and anti-alpha-actinin antibodies and markers of renal disease in patients with lupus nephritis: a prospective longitudinal study. <i>Arthritis Research and Therapy</i> , 2009, 11, R154.	3.5	107
17	Brain abnormalities in newly diagnosed neuropsychiatric lupus: Systematic MRI approach and correlation with clinical and laboratory data in a large multicenter cohort. <i>Autoimmunity Reviews</i> , 2015, 14, 153-159.	5.8	106
18	Antibodies to apolipoprotein Aâ€”, highâ€”density lipoprotein, and Câ€”reactive protein are associated with disease activity in patients with systemic lupus erythematosus. <i>Arthritis and Rheumatism</i> , 2010, 62, 845-854.	6.7	100

#	ARTICLE	IF	CITATIONS
19	Mood Disorders in Systemic Lupus Erythematosus: Results From an International Inception Cohort Study. <i>Arthritis and Rheumatology</i> , 2015, 67, 1837-1847.	5.6	98
20	2021 DORIS definition of remission in SLE: final recommendations from an international task force. <i>Lupus Science and Medicine</i> , 2021, 8, e000538.	2.7	97
21	British isles lupus assessment group 2004 index is valid for assessment of disease activity in systemic lupus erythematosus. <i>Arthritis and Rheumatism</i> , 2007, 56, 4113-4119.	6.7	96
22	Novel assays of thrombogenic pathogenicity in the antiphospholipid syndrome based on the detection of molecular oxidative modification of the major autoantigen $\beta_2$ -glycoprotein I. <i>Arthritis and Rheumatism</i> , 2011, 63, 2774-2782.	6.7	96
23	Prevalence of conventional and lupus-specific risk factors for cardiovascular disease in patients with systemic lupus erythematosus: A case-control study. <i>Arthritis and Rheumatism</i> , 2006, 55, 892-899.	6.7	95
24	Is $\beta$ -actinin a target for pathogenic anti-DNA antibodies in lupus nephritis?. <i>Arthritis and Rheumatism</i> , 2004, 50, 866-870.	6.7	90
25	The BILAG-2004 index is sensitive to change for assessment of SLE disease activity. <i>Rheumatology</i> , 2009, 48, 691-695.	1.9	90
26	The role of beta-2-glycoprotein I in health and disease associating structure with function: More than just APS. <i>Blood Reviews</i> , 2020, 39, 100610.	5.7	85
27	Headache in Systemic Lupus Erythematosus: Results From a Prospective, International Inception Cohort Study. <i>Arthritis and Rheumatism</i> , 2013, 65, 2887-2897.	6.7	84
28	Fibromyalgia. <i>BMJ, The</i> , 2014, 348, g1224-g1224.	6.0	84
29	Risk Factors for Clinical Coronary Heart Disease in Systemic Lupus Erythematosus: The Lupus and Atherosclerosis Evaluation of Risk (LASER) Study. <i>Journal of Rheumatology</i> , 2010, 37, 322-329.	2.0	83
30	16th International Congress on Antiphospholipid Antibodies Task Force Report on Antiphospholipid Syndrome Treatment Trends. <i>Lupus</i> , 2020, 29, 1571-1593.	1.6	80
31	Clinical associations of the metabolic syndrome in systemic lupus erythematosus: data from an international inception cohort. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, 1308-1314.	0.9	78
32	Review: Can we identify how programmes aimed at promoting self-management in musculoskeletal pain work and who benefits? A systematic review of subgroup analysis within RCTs. <i>European Journal of Pain</i> , 2011, 15, 775.e1-11.	2.8	75
33	Unmet Needs in the Pathogenesis and Treatment of Systemic Lupus Erythematosus. <i>Clinical Reviews in Allergy and Immunology</i> , 2018, 55, 352-367.	6.5	75
34	Short-term efficacy and safety of rituximab therapy in refractory systemic lupus erythematosus: results from the British Isles Lupus Assessment Group Biologics Register. <i>Rheumatology</i> , 2018, 57, 470-479.	1.9	73
35	Impact of early disease factors on metabolic syndrome in systemic lupus erythematosus: data from an international inception cohort. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 1530-1536.	0.9	70
36	Antinuclear Antibody-Negative Systemic Lupus Erythematosus in an International Inception Cohort. <i>Arthritis Care and Research</i> , 2019, 71, 893-902.	3.4	70

#	ARTICLE	IF	CITATIONS
37	Effects of Polyclonal IgG Derived from Patients with Different Clinical Types of the Antiphospholipid Syndrome on Monocyte Signaling Pathways. <i>Journal of Immunology</i> , 2010, 184, 6622-6628.	0.8	67
38	Proof-of-concept study demonstrating the pathogenicity of affinity-purified IgG antibodies directed to domain I of $\beta$ 2-glycoprotein I in a mouse model of anti-phospholipid antibody-induced thrombosis. <i>Rheumatology</i> , 2015, 54, 722-727.	1.9	67
39	Measuring IgA Anti- $\beta$ 2-Glycoprotein I and IgG/IgA Anti-Domain I Antibodies Adds Value to Current Serological Assays for the Antiphospholipid Syndrome. <i>PLoS ONE</i> , 2016, 11, e0156407.	2.5	66
40	How do antiphospholipid antibodies bind $\beta$ 2-glycoprotein I?. <i>Arthritis and Rheumatism</i> , 2003, 48, 2111-2121.	6.7	58
41	"It struck me that they didn't understand pain" The specialist pain clinic experience of patients with chronic musculoskeletal pain. <i>Arthritis and Rheumatism</i> , 2005, 53, 691-696.	6.7	56
42	Cerebrovascular Events in Systemic Lupus Erythematosus: Results From an International Inception Cohort Study. <i>Arthritis Care and Research</i> , 2018, 70, 1478-1487.	3.4	55
43	Psychosis in Systemic Lupus Erythematosus: Results From an International Inception Cohort Study. <i>Arthritis and Rheumatology</i> , 2019, 71, 281-289.	5.6	55
44	Rheumatoid Arthritis and Incidence of Twelve Initial Presentations of Cardiovascular Disease: A Population Record-Linkage Cohort Study in England. <i>PLoS ONE</i> , 2016, 11, e0151245.	2.5	50
45	25-Hydroxyvitamin D and Cardiovascular Disease in Patients With Systemic Lupus Erythematosus: Data From a Large International Inception Cohort. <i>Arthritis Care and Research</i> , 2014, 66, 1167-1176.	3.4	49
46	Sensitivity to Change and Minimal Important Differences of the LupusQoL in Patients With Systemic Lupus Erythematosus. <i>Arthritis Care and Research</i> , 2016, 68, 1505-1513.	3.4	45
47	Atherosclerosis in systemic lupus erythematosus. <i>Best Practice and Research in Clinical Rheumatology</i> , 2017, 31, 364-372.	3.3	45
48	Novel Three-Day, Community-Based, Nonpharmacological Group Intervention for Chronic Musculoskeletal Pain (COPERS): A Randomised Clinical Trial. <i>PLoS Medicine</i> , 2016, 13, e1002040.	8.4	45
49	Systematic analysis of sequences of anti-DNA antibodies—relevance to theories of origin and pathogenicity. <i>Lupus</i> , 2002, 11, 807-823.	1.6	44
50	Cross-talk between iNKT cells and monocytes triggers an atheroprotective immune response in SLE patients with asymptomatic plaque. <i>Science Immunology</i> , 2016, 1, .	11.9	44
51	Opioid prescribing for chronic musculoskeletal pain in UK primary care: results from a cohort analysis of the COPERS trial. <i>BMJ Open</i> , 2018, 8, e019491.	1.9	44
52	Antibodies to domain I of $\beta$ 2-glycoprotein I and IgA antiphospholipid antibodies in patients with "seronegative" antiphospholipid syndrome. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 317-319.	0.9	42
53	Flares after hydroxychloroquine reduction or discontinuation: results from the Systemic Lupus International Collaborating Clinics (SLICC) inception cohort. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, 370-378.	0.9	42
54	A Longitudinal Analysis of Outcomes of Lupus Nephritis in an International Inception Cohort Using a Multistate Model Approach. <i>Arthritis and Rheumatology</i> , 2016, 68, 1932-1944.	5.6	40

#	ARTICLE	IF	CITATIONS
55	Neuropsychiatric events in systemic lupus erythematosus: a longitudinal analysis of outcomes in an international inception cohort using a multistate model approach. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 356-362.	0.9	40
56	Peripheral Nervous System Disease in Systemic Lupus Erythematosus: Results From an International Inception Cohort Study. <i>Arthritis and Rheumatology</i> , 2020, 72, 67-77.	5.6	39
57	Glucocorticoid use and factors associated with variability in this use in the Systemic Lupus International Collaborating Clinics Inception Cohort. <i>Rheumatology</i> , 2018, 57, 677-687.	1.9	37
58	Immunoglobulin variable region sequences of human monoclonal anti-DNA, antibodies. <i>Seminars in Arthritis and Rheumatism</i> , 1998, 28, 141-154.	3.4	36
59	A systematic analysis of sequences of human antiphospholipid and anti-β <sub>2</sub> -glycoprotein I antibodies: The importance of somatic mutations and certain sequence motifs. <i>Seminars in Arthritis and Rheumatism</i> , 2003, 32, 246-265.	3.4	36
60	Numerical scoring for the Classic BILAG index. <i>Rheumatology</i> , 2009, 48, 1548-1552.	1.9	35
61	Construction of a Frailty Index as a Novel Health Measure in Systemic Lupus Erythematosus. <i>Journal of Rheumatology</i> , 2020, 47, 72-81.	2.0	34
62	Anti-DNA antibodies - overview of assays and clinical correlations. <i>Lupus</i> , 2002, 11, 770-773.	1.6	33
63	A novel expression system of domain I of human beta <sub>2</sub> glycoprotein I in <i>Escherichia coli</i> . <i>BMC Biotechnology</i> , 2006, 6, 8.	3.3	33
64	Impact of glucocorticoids on the incidence of lupus-related major organ damage: a systematic literature review and meta-regression analysis of longitudinal observational studies. <i>Lupus Science and Medicine</i> , 2021, 8, e000590.	2.7	31
65	Arginine Residues Are Important in Determining the Binding of Human Monoclonal Antiphospholipid Antibodies to Clinically Relevant Antigens. <i>Journal of Immunology</i> , 2006, 177, 1729-1736.	0.8	30
66	PEGylated drugs in rheumatology--why develop them and do they work?. <i>Rheumatology</i> , 2014, 53, 391-396.	1.9	30
67	The importance of somatic mutations in the V <sub>H</sub> gene 2a2 in human monoclonal anti-DNA antibodies. <i>Journal of Molecular Biology</i> , 2001, 307, 149-160.	4.2	29
68	Relationship between damage clustering and mortality in systemic lupus erythematosus in early and late stages of the disease: cluster analyses in a large cohort from the Spanish Society of Rheumatology Lupus Registry. <i>Rheumatology</i> , 2016, 55, 1243-1250.	1.9	28
69	Smoking Is the Most Significant Modifiable Lung Cancer Risk Factor in Systemic Lupus Erythematosus. <i>Journal of Rheumatology</i> , 2018, 45, 393-396.	2.0	27
70	Soluble urokinase plasminogen activator receptor (suPAR) levels predict damage accrual in patients with recent-onset systemic lupus erythematosus. <i>Journal of Autoimmunity</i> , 2020, 106, 102340.	6.5	27
71	Molecular and genetic characterizations of five pathogenic and two non-pathogenic monoclonal antiphospholipid antibodies. <i>Molecular Immunology</i> , 2002, 39, 299-311.	2.2	26
72	Study of Flare Assessment in Systemic Lupus Erythematosus Based on Paper Patients. <i>Arthritis Care and Research</i> , 2018, 70, 98-103.	3.4	26

#	ARTICLE	IF	CITATIONS
73	Prediction of Damage Accrual in Systemic Lupus Erythematosus Using the Systemic Lupus International Collaborating Clinics Frailty Index. <i>Arthritis and Rheumatology</i> , 2020, 72, 658-666.	5.6	26
74	Serum Metabolomic Signatures Can Predict Subclinical Atherosclerosis in Patients With Systemic Lupus Erythematosus. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2021, 41, 1446-1458.	2.4	26
75	Relative importance of different human aPL derived heavy and light chains in the binding of aPL to cardiolipin. <i>Molecular Immunology</i> , 2003, 40, 49-60.	2.2	25
76	Evaluating the Properties of a Frailty Index and Its Association With Mortality Risk Among Patients With Systemic Lupus Erythematosus. <i>Arthritis and Rheumatology</i> , 2019, 71, 1297-1307.	5.6	25
77	Gene expression profiling identifies distinct molecular signatures in thrombotic and obstetric antiphospholipid syndrome. <i>Journal of Autoimmunity</i> , 2018, 93, 114-123.	6.5	24
78	Use of a strategy based on calculated risk scores in managing cardiovascular risk factors in a large British cohort of patients with systemic lupus erythematosus. <i>Rheumatology</i> , 2008, 48, 573-575.	1.9	23
79	Pain management for chronic musculoskeletal conditions: the development of an evidence-based and theory-informed pain self-management course. <i>BMJ Open</i> , 2013, 3, e003534.	1.9	23
80	IgG anti-apolipoprotein A-1 antibodies in patients with systemic lupus erythematosus are associated with disease activity and corticosteroid therapy: an observational study. <i>Arthritis Research and Therapy</i> , 2015, 17, 26.	3.5	23
81	Economic Evaluation of Damage Accrual in an International Systemic Lupus Erythematosus Inception Cohort Using a Multistate Model Approach. <i>Arthritis Care and Research</i> , 2020, 72, 1800-1808.	3.4	23
82	The critical role of arginine residues in the binding of human monoclonal antibodies to cardiolipin. <i>Arthritis Research</i> , 2005, 7, R47.	2.0	22
83	Comparison of the 2019 European Alliance of Associations for Rheumatology/American College of Rheumatology Systemic Lupus Erythematosus Classification Criteria With Two Sets of Earlier Systemic Lupus Erythematosus Classification Criteria. <i>Arthritis Care and Research</i> , 2021, 73, 1231-1235.	3.4	22
84	Pathological mechanisms of abnormal iron metabolism and mitochondrial dysfunction in systemic lupus erythematosus. <i>Expert Review of Clinical Immunology</i> , 2021, 17, 957-967.	3.0	22
85	Economic Evaluation of Lupus Nephritis in the Systemic Lupus International Collaborating Clinics Inception Cohort Using a Multistate Model Approach. <i>Arthritis Care and Research</i> , 2018, 70, 1294-1302.	3.4	21
86	Improving the self-management of chronic pain: COping with persistent Pain, Effectiveness Research in Self-management (COPERS). <i>Programme Grants for Applied Research</i> , 2016, 4, 1-440.	1.0	21
87	Molecular Cloning and Expression of the Fabs of Human Autoantibodies in <i>Escherichia coli</i> . <i>Journal of Biological Chemistry</i> , 2000, 275, 35129-35136.	3.4	19
88	Thrombin Binding Predicts the Effects of Sequence Changes in a Human Monoclonal Antiphospholipid Antibody on Its In Vivo Biologic Actions. <i>Journal of Immunology</i> , 2009, 182, 4836-4843.	0.8	19
89	Imaging Assessment of Cardiovascular Disease in Systemic Lupus Erythematosus. <i>Clinical and Developmental Immunology</i> , 2012, 2012, 1-7.	3.3	19
90	Damage accrual and mortality over long-term follow-up in 300 patients with systemic lupus erythematosus in a multi-ethnic British cohort. <i>Rheumatology</i> , 2020, 59, 524-533.	1.9	19

#	ARTICLE	IF	CITATIONS
91	15th International Congress on Antiphospholipid Antibodies Task Force on Antiphospholipid Syndrome Treatment Trends Report. , 2017, , 317-338.		19
92	Efficacy of an out-patient pain management programme for people with joint hypermobility syndrome. Clinical Rheumatology, 2014, 33, 1665-1669.	2.2	18
93	A critical analysis of the tools to evaluate neuropsychiatric lupus. Lupus, 2017, 26, 504-509.	1.6	17
94	Antiphospholipid antibodies enhance rat neonatal cardiomyocyte apoptosis in an in vitro hypoxia/reoxygenation injury model via p38 MAPK. Cell Death and Disease, 2018, 8, e2549-e2549.	6.3	17
95	Accrual of Atherosclerotic Vascular Events in a Multicenter Inception Systemic Lupus Erythematosus Cohort. Arthritis and Rheumatology, 2020, 72, 1734-1740.	5.6	17
96	Evaluating the conformation of recombinant domain I of $\beta$ 2-glycoprotein I and its interaction with human monoclonal antibodies. Molecular Immunology, 2011, 49, 56-63.	2.2	16
97	Anti-factor Xa antibodies in patients with antiphospholipid syndrome and their effects upon coagulation assays. Arthritis Research and Therapy, 2015, 17, 47.	3.5	16
98	Important determinants of self-efficacy in patients with chronic musculoskeletal pain. Journal of Rheumatology, 2004, 31, 1187-92.	2.0	16
99	Somatic mutations to arginine residues affect the binding of human monoclonal antibodies to DNA, histones, SmD and Ro antigen. Molecular Immunology, 2004, 40, 745-758.	2.2	15
100	Interactions of human monoclonal and polyclonal antiphospholipid antibodies with serine proteases involved in hemostasis. Arthritis and Rheumatism, 2011, 63, 3512-3521.	6.7	15
101	Effectiveness and cost-effectiveness of a novel, group self-management course for adults with chronic musculoskeletal pain: study protocol for a multicentre, randomised controlled trial (COPERS). BMJ Open, 2013, 3, e002492.	1.9	15
102	Osteopontin and Disease Activity in Patients with Recent-onset Systemic Lupus Erythematosus: Results from the SLICC Inception Cohort. Journal of Rheumatology, 2019, 46, 492-500.	2.0	15
103	Can we validate a clinical score to predict the risk of severe infection in patients with systemic lupus erythematosus? A longitudinal retrospective study in a British Cohort. BMJ Open, 2019, 9, e028697.	1.9	15
104	Stable expression of a recombinant human antinucleosome antibody to investigate relationships between antibody sequence, binding properties, and pathogenicity. Arthritis Research and Therapy, 2005, 7, R971.	3.5	14
105	The association between IgG and IgM antibodies against cardiolipin, $\beta$ 2-glycoprotein I and Domain I of $\beta$ 2-glycoprotein I with disease profile in patients with multiple sclerosis. Molecular Immunology, 2016, 75, 161-167.	2.2	14
106	PEGylated Domain I of Beta-2-Glycoprotein I Inhibits the Binding, Coagulopathic, and Thrombogenic Properties of IgG From Patients With the Antiphospholipid Syndrome. Frontiers in Immunology, 2018, 9, 2413.	4.8	14
107	Antiphospholipid antibody levels in early systemic lupus erythematosus: are they associated with subsequent mortality and vascular events?. Rheumatology, 2020, 59, 146-152.	1.9	14
108	Lower vitamin D is associated with metabolic syndrome and insulin resistance in systemic lupus: data from an international inception cohort. Rheumatology, 2021, 60, 4737-4747.	1.9	14

#	ARTICLE	IF	CITATIONS
109	Cancer Risk in a Large Inception Systemic Lupus Erythematosus Cohort: Effects of Demographic Characteristics, Smoking, and Medications. <i>Arthritis Care and Research</i> , 2021, 73, 1789-1795.	3.4	13
110	Arginine mutation alters binding of a human monoclonal antibody to antigens linked to systemic lupus erythematosus and the antiphospholipid syndrome. <i>Arthritis and Rheumatism</i> , 2007, 56, 2392-2401.	6.7	12
111	Low aspirin use and high prevalence of pre-eclampsia risk factors among pregnant women in a multinational SLE inception cohort. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 1010-1012.	0.9	12
112	New therapeutic avenues in SLE. <i>Best Practice and Research in Clinical Rheumatology</i> , 2015, 29, 794-809.	3.3	11
113	Going viral in rheumatology: using social media to show that mechanistic research is relevant to patients with lupus and antiphospholipid syndrome. <i>Rheumatology Advances in Practice</i> , 2018, 2, rky003.	0.7	11
114	Antiphospholipid Antibodies to Domain I of Beta-2-Glycoprotein I Show Different Subclass Predominance in Comparison to Antibodies to Whole Beta-2-glycoprotein I. <i>Frontiers in Immunology</i> , 2018, 9, 2244.	4.8	11
115	Taking a closer look at biologic therapy for SLE. <i>Nature Reviews Rheumatology</i> , 2014, 10, 71-72.	8.0	10
116	Prediction of hospitalizations in systemic lupus erythematosus using the Systemic Lupus International Collaborating Clinics Frailty Index (SLICCâ€FI). <i>Arthritis Care and Research</i> , 2020, , .	3.4	9
117	Outcomes of membranous and proliferative lupus nephritis â€ analysis of a single-centre cohort with more than 30 years of follow-up. <i>Rheumatology</i> , 2020, 59, 3314-3323.	1.9	9
118	Longitudinal analysis of ANA in the Systemic Lupus International Collaborating Clinics (SLICC) Inception Cohort. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, 1143-1150.	0.9	9
119	Development of a high yield expression and purification system for Domain I of Beta-2-glycoprotein I for the treatment of APS. <i>BMC Biotechnology</i> , 2015, 15, 104.	3.3	8
120	Oxidation of Î²2-glycoprotein I associates with IgG antibodies to domain I in patients with antiphospholipid syndrome. <i>PLoS ONE</i> , 2017, 12, e0186513.	2.5	8
121	Use of combined hormonal contraceptives among women with systemic lupus erythematosus with and without medical contraindications to oestrogen. <i>Rheumatology</i> , 2019, 58, 1259-1267.	1.9	8
122	Structureâ€function analysis and the molecular origins of anti-DNA antibodies in systemic lupus erythematosus. <i>Expert Reviews in Molecular Medicine</i> , 1999, 1, 1-28.	3.9	7
123	Molecular expression systems for anti-DNA antibodiesâ€1. <i>Lupus</i> , 2002, 11, 824-832.	1.6	7
124	Origin and structure of autoantibodies and antigens in autoimmune rheumatic diseases. <i>Lupus</i> , 2008, 17, 232-235.	1.6	7
125	Factor Xa Mediates Calcium Flux in Endothelial Cells and is Potentiated by Igg From Patients With Lupus and/or Antiphospholipid Syndrome. <i>Scientific Reports</i> , 2017, 7, 10788.	3.3	7
126	Neuropsychiatric Events in Systemic Lupus Erythematosus: Predictors of Occurrence and Resolution in a Longitudinal Analysis of an International Inception Cohort. <i>Arthritis and Rheumatology</i> , 2021, 73, 2293-2302.	5.6	7

#	ARTICLE	IF	CITATIONS
127	Evaluating the Construct of Damage in Systemic Lupus Erythematosus. <i>Arthritis Care and Research</i> , 2023, 75, 998-1006.	3.4	7
128	Anti-DNA antibodies structure and function. <i>Lupus</i> , 2002, 11, 776-779.	1.6	6
129	Testing a support programme for opioid reduction for people with chronic non-malignant pain: the I-WOTCH randomised controlled trial protocol. <i>BMJ Open</i> , 2019, 9, e028937.	1.9	6
130	Pathogenic autoantibodies from patients with lupus nephritis cause reduced tyrosine phosphorylation of podocyte proteins, including tubulin. <i>Lupus Science and Medicine</i> , 2014, 1, e000013.	2.7	5
131	Flares in patients with systemic lupus erythematosus. <i>Rheumatology</i> , 2021, 60, 3262-3267.	1.9	5
132	Management of antiphospholipid syndrome. <i>Clinical Rheumatology</i> , 2020, 39, 2111-2114.	2.2	5
133	Antiphospholipid Antibody Testing in a General Population Sample from the USA: An Administrative Database Study. <i>Scientific Reports</i> , 2020, 10, 3102.	3.3	5
134	Serum nitrated nucleosome levels in patients with systemic lupus erythematosus: a retrospective longitudinal cohort study. <i>Arthritis Research and Therapy</i> , 2014, 16, R48.	3.5	4
135	Antinuclear Antibodies, Antibodies to DNA, Histones, and Nucleosomes. , 2019, , 355-365.		4
136	Survival analysis of mortality and development of lupus nephritis in patients with systemic lupus erythematosus up to 40 years of follow-up. <i>Rheumatology</i> , 2022, 62, 200-208.	1.9	4
137	Extent of vascular plaque predicts future cardiovascular events in patients with systemic lupus erythematosus. <i>Rheumatology</i> , 2022, 62, 225-233.	1.9	4
138	The role of in vitro expression systems in the investigation of antibodies to DNA. <i>Seminars in Arthritis and Rheumatism</i> , 1998, 28, 130-139.	3.4	3
139	Menorrhagia: an underappreciated problem in pre-menopausal women with systemic lupus erythematosus. <i>Lupus</i> , 2019, 28, 916-917.	1.6	3
140	Total plaque area and plaque echogenicity are novel measures of subclinical atherosclerosis in patients with systemic lupus erythematosus. <i>Rheumatology</i> , 2021, 60, 4185-4198.	1.9	3
141	Specific domain V reduction of beta-2-glycoprotein I induces protein flexibility and alters pathogenic antibody binding. <i>Scientific Reports</i> , 2021, 11, 4542.	3.3	3
142	Comparison of Responsiveness of British Isles Lupus Assessment Group 2004 Index, Systemic Lupus Erythematosus Disease Activity Index 2000, and British Isles Lupus Assessment Group 2004 Systems Tally. <i>Arthritis Care and Research</i> , 2022, 74, 1623-1630.	3.4	3
143	Anti-beta 2 glycoprotein I IgA in the SLICC classification criteria dataset. <i>Lupus</i> , 2021, 30, 096120332110142.	1.6	3
144	Mechanisms of Antiphospholipid Antibody-Mediated Thrombosis. , 2017, , 77-116.		3

#	ARTICLE	IF	CITATIONS
145	Clinical and Prognostic Significance of Non-criteria Antiphospholipid Antibody Tests. , 2017, , 171-187.		3
146	Red cell distribution width correlates with fatigue levels in a diverse group of patients with systemic lupus erythematosus irrespective of anaemia status. Clinical and Experimental Rheumatology, 2019, 37, 852-854.	0.8	3
147	Lessons from Sequence Analysis of Monoclonal Antiphospholipid Antibodies. , 2006, , 470-491.		2
148	Structure-Function Relationships in Anti-DNA and Anti-Phospholipid Antibodies and their Relevance to the Pathogenesis of Disease. Current Rheumatology Reviews, 2008, 4, 2-11.	0.8	2
149	The potential overlapping populations for treatment with belimumab and rituximab using current NHS England and National Institute for Health and Care Excellence Guidelines in England and Wales. Rheumatology, 2017, 56, 1041-1043.	1.9	2
150	132â€fGoing viral in rheumatology: a rapid, cost-effective method of obtaining patient opinion about mechanistic research in SLE and APSA. Rheumatology, 2018, 57, .	1.9	2
151	Domain I of Î²2GPI is capable of blocking serum IgA antiphospholipid antibodies binding inÂvitro: an effect enhanced by PEGylation. Lupus, 2019, 28, 893-897.	1.6	2
152	Structure and function of autoantibodies and their role in autoimmune rheumatic diseases. Expert Review of Clinical Immunology, 2006, 2, 225-236.	3.0	1
153	Nitrated nucleosome levels and neuropsychiatric events in systemic lupus erythematosus; a multi-center retrospective case-control study. Arthritis Research and Therapy, 2017, 19, 287.	3.5	1
154	140â€fEvaluating the prevalence of iron deficiency and anaemia in systemic lupus erythematosus. Rheumatology, 2018, 57, .	1.9	1
155	Why Do Patients With Systemic Lupus Erythematosus Suffer Pain?. Journal of Rheumatology, 2021, 48, 1195-1197.	2.0	1
156	Do high-sensitivity C-reactive protein levels help predict risk of cardiovascular disease in patients with osteoarthritis?. Nature Clinical Practice Rheumatology, 2008, 4, 122-123.	3.2	0
157	The Research that Time Forgot. British Journal of Hospital Medicine (London, England: 2005), 2013, 74, 702-703.	0.5	0
158	316.â€fINCREASED RISK OF CARDIOVASCULAR DISEASE IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS WHO HAVE ASYMPTOMATIC PLAQUE ON VASCULAR ULTRASOUND: A 5 YEAR FOLLOW-UP STUDY. Rheumatology, 2017, 56, .	1.9	0
159	109.â€fTREAT TO TARGET IN LUPUS. Rheumatology, 2017, 56, .	1.9	0
160	O34.â€fANTI-PHOSPHOLIPID ANTIBODIES DIFFERENTIALLY REGULATE THE EXPRESSION AND ACTIVITY OF THE LYSOSOMAL PROTEASES WITH EFFECTS UPON MONOCYTE AUTOPHAGY. Rheumatology, 2017, 56, .	1.9	0
161	239.â€fPEGYLATED DOMAIN I OF BETA-2-GLYCOPROTEIN I PREVENTS THROMBOSIS IN A MOUSE MODEL. Rheumatology, 2017, 56, .	1.9	0
162	O64.â€fFLARES IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS. Rheumatology, 2017, 56, .	1.9	0

#	ARTICLE	IF	CITATIONS
163	Managing conventional cardiovascular risk factors in the lupus clinic – what can we achieve?. <i>Lupus</i> , 2018, 27, 172-173.	1.6	0
164	Adult SLE: survivors from childhood onset. <i>Rheumatology</i> , 2018, 57, .	1.9	0
165	Functional iron deficiency: a potential novel mechanism for fatigue in systemic lupus erythematosus. <i>Rheumatology</i> , 2018, 57, .	1.9	0
166	Evaluating the prevalence of heavy menstrual bleeding (menorrhagia) in patients with systemic lupus erythematosus. <i>Rheumatology</i> , 2018, 57, .	1.9	0
167	CS-07...Economic evaluation of damage accrual in an international SLE inception cohort. , 2018, , .		0
168	Disease trends and phenotypes among different age groups: a study in lupus. <i>Rheumatology</i> , 2018, 57, .	1.9	0
169	Examining the modulatory effects of anti-serine protease antibodies upon factor Xa, thrombin and complement interactions. <i>Rheumatology</i> , 2018, 57, .	1.9	0
170	Antiphospholipase A2 receptor antibodies, a marker of idiopathic membranous nephropathy, are not present in membranous lupus nephritis. <i>Rheumatology</i> , 2019, 58, .	1.9	0
171	Both Domain I and PEGylated Domain I of Beta-2-Glycoprotein I (Î²2GPI) are capable of inhibiting IgA APS antibody binding. <i>Rheumatology</i> , 2019, 58, .	1.9	0
172	Invariant natural killer T cells in RA and CVD. <i>Rheumatology</i> , 2019, 58, .	1.9	0
173	Baseline characteristics of patients with lupus nephritis requiring rituximab therapy: results from the British Isles Lupus Assessment Group Biologics Register (BILAG-BR). <i>Rheumatology</i> , 2019, 58, .	1.9	0
174	Modulation of monocyte autophagy as a therapeutic target in antiphospholipid syndrome. <i>Rheumatology</i> , 2019, 58, .	1.9	0
175	Anti-phospholipid antibody syndrome. <i>Rheumatology</i> , 2019, 58, .	1.9	0
176	Atherosclerosis in lupus: can early detection be achieved and acted upon?. <i>Rheumatology</i> , 2019, 58, .	1.9	0
177	How to investigate: Very early inflammatory rheumatic diseases. <i>Best Practice and Research in Clinical Rheumatology</i> , 2019, 33, 101454.	3.3	0
178	Antilipoprotein and Antiendothelial Cell Antibodies. , 2019, , 375-376.		0
179	Orthopaedic surgical interventions in a cohort of patients with hypermobility related disorders, compared with chronic pain syndrome patients in a tertiary referral centre. <i>Rheumatology</i> , 2020, 59, .	1.9	0
180	Predictors of renal survival in a cohort of patients with lupus nephritis with more than 30 years of follow-up. <i>Rheumatology</i> , 2020, 59, .	1.9	0

#	ARTICLE	IF	CITATIONS
181	P172â€¦Anti-domain I positivity in SLE at diagnosis is predictive of atherosclerotic plaque development. Rheumatology, 2020, 59, .	1.9	0
182	P59â€¦Predictors of renal survival in a cohort of patients with lupus nephritis with more than 30 years of follow-up. , 2020, , .		0
183	P145â€¦Membranous and proliferative lupus nephritis â€” analysis of a nationwide multicentre cohort. , 2020, , .		0
184	P21â€¦Investigation of possible pathogenic autoantibodies in membranous lupus nephritis. , 2020, , .		0
185	P31â€¦Anti-domain I positivity in SLE at diagnosis is predictive of atherosclerotic plaque development. , 2020, , .		0
186	P42â€¦Disease activity, impaired iron transport and failed sequestration: a novel mechanism for anaemia in systemic lupus erythematosus. , 2020, , .		0
187	Unusual presentations in patients with systemic lupus erythematosus: a result of disease activity or something else?. British Journal of Hospital Medicine (London, England: 2005), 2020, 81, 1-3.	0.5	0
188	Antiphospholipid syndrome and pregnancy. British Journal of Midwifery, 2021, 29, 308-309.	0.4	0
189	1704â€¦Identifying clusters of longitudinal autoantibody profiles associated with systemic lupus erythematosus disease outcomes. , 2021, , .		0
190	PEGylated Domain I of Beta-2-Glycoprotein I Inhibits Thrombosis in a Chronic Mouse Model of the Antiphospholipid Syndrome. Frontiers in Immunology, 2022, 13, 842923.	4.8	0
191	The BILAG-2004 index is associated with development of new damage in SLE. Rheumatology, 0, , .	1.9	0